In the TCGA cohort, the GSEA suggested that the cell cycle, DNA replication, Parkinson’s disease, pyrimidine metabolism, and ribosome pathways were activated in patients with high-risk scores; meanwhile, allograft rejection, asthma, the intestinal immune network for IgA production, primary immunodeficiency, and systemic lupus erythematosus pathways were activated in patients with low-risk scores (Figures 6A, B). The gene discussed is CD79A; the disease is systemic lupus erythematosus.